First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811
Year: 2020
Type: article
Study design: Study Protocol
Abstract: Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov).
Source: Future Oncology
Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Seoul National University, Yale Cancer Center, Smilow Cancer Hospital, The University of Osaka, National Cancer Center Hospital East, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Universitair Ziekenhuis Leuven, KU Leuven, Merck & Co., Inc., Rahway, NJ, USA (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Award: Cancer Center Support Grant
OpenAlex ID: W3098108773
